KalVista Pharmaceuticals’ (KALV) “Overweight” Rating Reiterated at Cantor Fitzgerald

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a research note issued on Monday,Benzinga reports.

KALV has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th.

KalVista Pharmaceuticals Stock Up 1.1 %

NASDAQ:KALV opened at $9.44 on Monday. KalVista Pharmaceuticals has a 52 week low of $7.39 and a 52 week high of $16.88. The stock’s 50-day moving average price is $10.81 and its 200-day moving average price is $11.80. The stock has a market capitalization of $466.52 million, a PE ratio of -2.59 and a beta of 0.85.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 14,400 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $133,344.00. Following the completion of the sale, the chief executive officer now directly owns 266,598 shares in the company, valued at $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 8,077 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now owns 94,199 shares in the company, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 32,291 shares of company stock worth $304,086. Corporate insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in KALV. Price T Rowe Associates Inc. MD grew its holdings in shares of KalVista Pharmaceuticals by 4.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after purchasing an additional 944 shares during the period. Bank of New York Mellon Corp grew its stake in shares of KalVista Pharmaceuticals by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 135,600 shares of the specialty pharmaceutical company’s stock valued at $1,597,000 after buying an additional 23,547 shares during the period. nVerses Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals during the 2nd quarter worth approximately $25,000. Rhumbline Advisers raised its position in shares of KalVista Pharmaceuticals by 12.5% during the 2nd quarter. Rhumbline Advisers now owns 53,228 shares of the specialty pharmaceutical company’s stock valued at $627,000 after buying an additional 5,908 shares during the period. Finally, ClariVest Asset Management LLC raised its position in shares of KalVista Pharmaceuticals by 2.8% during the 2nd quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock valued at $673,000 after buying an additional 1,535 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).